Valneva SE

French vaccine producer

ISIN FR0004056851 LEI 969500DIVIP5VKNW4948
Follow Valneva Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €174.7M +3% vs prior year
Net income −€115.2M −840.6% vs prior year
EPS, diluted −€0.68 −750% vs prior year
Operating cash flow −€52.9M +21.3% vs prior year
Revenue by fiscal year
€110.3M
€348.1M
€361.3M
€153.7M
€169.6M
€174.7M
FY20 FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−€200M€0€200M€400MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€174.7M−€115.2M
FY24€169.6M−€12.2M
FY23€153.7M−€101.4M
FY22€361.3M−€143.3M
FY21€348.1M−€73.4M
FY20€110.3M−€64.4M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2538.7%−47%−66%
FY2441.9%7.9%−7.2%
FY2334.4%−53.4%−66%
FY2210.2%−31.4%−39.7%
FY2146%−17.6%−21.1%
FY2050.8%−50%−58.4%
Free cash flowOperating cash flow minus capital expenditure
−€300M−€200M−€100M€0€100M€200MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−€57.3M
FY24−€81.1M
FY23−€217M
FY22−€274.6M
FY21−€15.3M
FY20€118.8M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Valneva
  • Healthcare median
−100%−75%−50%−25%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearValnevaHealthcare median
FY25−66%−30.6%
FY24−7.2%−47%
FY23−66%−58%
FY22−39.7%−80.4%
FY21−21.1%−71.9%
FY20−58.4%−62.2%